moxifloxacin has been researched along with labetalol in 6 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (labetalol) | Trials (labetalol) | Recent Studies (post-2010) (labetalol) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 1,980 | 450 | 327 |
| Protein | Taxonomy | moxifloxacin (IC50) | labetalol (IC50) |
|---|---|---|---|
| Beta-2 adrenergic receptor | Homo sapiens (human) | 0.016 | |
| Aldo-keto reductase family 1 member B1 | Rattus norvegicus (Norway rat) | 3.354 | |
| Beta-1 adrenergic receptor | Homo sapiens (human) | 0.01 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 0.8 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.393 | |
| Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 3.354 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.521 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.393 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 3.037 | |
| Sodium-dependent dopamine transporter | Homo sapiens (human) | 1.607 | |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | 1.815 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for moxifloxacin and labetalol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for moxifloxacin and labetalol
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |